As of Dec 8, 2018 Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB) Sellers Decreased Their Shorts By 9.25%

Change of 9.25% for Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB)’s shorted shares was reported. In December was published ZLAB’s total 1.33 million shorted shares by FINRA. The down change of 9.25% from 1.47M shares was reported. With Average volume 104,600, ZLAB’s previous position will take 13 days to recover. Float short on Zai Lab Limited – American Depositary Shares is 9.87%.

The stock increased 4.36% or $0.86 during the last trading session, hitting $20.59.Currently Zai Lab Limited is after 0.00% change in last December 8, 2017. ZLAB has 147,087 shares volume. The stock underperformed the S&P500 by 15.62%.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China.The firm is valued at $1.20 billion. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.Last it reported negative earnings.

For more Zai Lab Limited (NASDAQ:ZLAB) news posted recently go to:,,, or The titles are as follows: “Your Daily Pharma Scoop: Arena Positive, Omeros’s New Designation, Zai Lab’s Phase 3 Dosing Begins – Seeking Alpha” posted on August 29, 2018, “George Soros Bought These 2 Healthcare Stocks in the Third Quarter – The Motley Fool” on December 03, 2018, “Zai Lab’s (ZLAB) CEO Samantha Du Discusses License and Collaboration Agreement with Novocure Conference (Transcript) – Seeking Alpha” with a publish date: September 13, 2018, “3 Things In Biotech You Should Learn Today: September 30, 2017 – Seeking Alpha” and the last “Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer – GlobeNewswire” with publication date: September 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.